GBP/USD Forecast: Further slides on the table
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFERGBP/USD Current price: 1.3731
- UK authorities said the risk of blood clots from the AstraZeneca shot is higher for under-30s.
- The March UK Markit Service PMI came in at 56.3, slightly below the 56.8 expected.
- GBP/USD is bearish in the near-term, pressuring a support level at 1.3720.
The GBP/USD plunged to 1.3728, as several factors combined to put pressure on the pound. The March UK Markit Service PMI came in at 56.3, below the 56.8 expected, although still within expansion levels. The European Medicines Agency finalized its review of the AstraZeneca vaccine and concluded that blood clots are a “very rare side effect” of the shot. The UK said that the risk of blood clots is higher for under-30s, and the local authority recommended providing a different vaccine for that age group. Meanwhile, the UK has started using the Moderna vaccine after buying 17 million doses of the jab.
In the meantime, the greenback remained under selling pressure, as US Treasury yields remained subdued, while equities traded with a soft tone, with most major indexes down for the day. On Thursday, Markit will publish the March Construction PMI, foreseen at 54.6 from 53.3 in the previous month.
GBP/USD short-term technical outlook
The GBP/USD pair trades near its daily lows around 1.3740 as the day comes to an end, firmly bearish according to the 4-hour chart. In the mentioned time frame, the pair has extended its slump below all of its moving averages, with the 20 SMA turning south between the longer ones. Technical indicators reached oversold readings, the Momentum maintaining its downward strength and the RSI stable at around 31, all of which support another leg lower, mainly on a break below 1.3720, the immediate support.
Support levels: 1.3720 1.3680 1.3640
Resistance levels: 1.3770 1.3810 1.3865
GBP/USD Current price: 1.3731
- UK authorities said the risk of blood clots from the AstraZeneca shot is higher for under-30s.
- The March UK Markit Service PMI came in at 56.3, slightly below the 56.8 expected.
- GBP/USD is bearish in the near-term, pressuring a support level at 1.3720.
The GBP/USD plunged to 1.3728, as several factors combined to put pressure on the pound. The March UK Markit Service PMI came in at 56.3, below the 56.8 expected, although still within expansion levels. The European Medicines Agency finalized its review of the AstraZeneca vaccine and concluded that blood clots are a “very rare side effect” of the shot. The UK said that the risk of blood clots is higher for under-30s, and the local authority recommended providing a different vaccine for that age group. Meanwhile, the UK has started using the Moderna vaccine after buying 17 million doses of the jab.
In the meantime, the greenback remained under selling pressure, as US Treasury yields remained subdued, while equities traded with a soft tone, with most major indexes down for the day. On Thursday, Markit will publish the March Construction PMI, foreseen at 54.6 from 53.3 in the previous month.
GBP/USD short-term technical outlook
The GBP/USD pair trades near its daily lows around 1.3740 as the day comes to an end, firmly bearish according to the 4-hour chart. In the mentioned time frame, the pair has extended its slump below all of its moving averages, with the 20 SMA turning south between the longer ones. Technical indicators reached oversold readings, the Momentum maintaining its downward strength and the RSI stable at around 31, all of which support another leg lower, mainly on a break below 1.3720, the immediate support.
Support levels: 1.3720 1.3680 1.3640
Resistance levels: 1.3770 1.3810 1.3865
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.